File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Phase I combination of sorafenib and erlotinib therapy in solid tumors: Safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort

TitlePhase I combination of sorafenib and erlotinib therapy in solid tumors: Safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort
Authors
Issue Date2010
Citation
Molecular Cancer Therapeutics, 2010, v. 9, n. 3, p. 751-760 How to Cite?
AbstractThe aims of this study were to further define the safety of sorafenib and erlotinib, given at their full approved monotherapy doses, and to correlate pharmacokinetic and pharmacodynamic markers with clinical outcome. In addition, a novel pharmacodynamic marker based on the real-time measurement of RAF signal transduction capacity (STC) is described. Sorafenib was administered alone for a 1-week run-in period, and then both drugs were given together continuously. RAF STC was assessed in peripheral blood monocytes prior to erlotinib initiation. Epidermal growth factor receptor (EGFR) expression and K-RAS mutations were measured in archival tumor samples. Changes in pERK and CD31 were determined in fresh tumor biopsies obtained pretreatment, prior to erlotinib dosing, and during the administration of both drugs. In addition, positron emission tomography-computed tomography scans and pharmacokinetic assessments were done. Eleven patients received a total of 57 cycles (median, 5; range, 1-10). Only four patients received full doses of both drugs for the entire study course, with elevation of liver enzymes being the main reason for dose reductions and delays. Among 10 patients evaluable for response, 8 experienced tumor stabilization of ≥4 cycles. Pharmacokinetic analysis revealed no significant interaction of erlotinib with sorafenib. Sorafenib-induced decrease in RAF-STC showed statistically significant correlation with time-to-progression in seven patients. Other pharmacodynamic markers did not correlate with clinical outcome. This drug combination resulted in promising clinical activity in solid tumor patients although significant toxicity warrants close monitoring. RAF-STC deserves further study as a predictive marker for sorafenib. ©2010 AACR.
Persistent Identifierhttp://hdl.handle.net/10722/291953
ISSN
2023 Impact Factor: 5.3
2023 SCImago Journal Rankings: 2.270
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorQuintela-Fandino, Miguel-
dc.contributor.authorLe Tourneau, Christophe-
dc.contributor.authorDuran, Ignacio-
dc.contributor.authorChen, Eric X.-
dc.contributor.authorWang, Lisa-
dc.contributor.authorTsao, Ming-
dc.contributor.authorBandarchi-Chamkhaleh, Bizhan-
dc.contributor.authorPham, Nhu Ann-
dc.contributor.authorDo, Trevor-
dc.contributor.authorMacLean, Martha-
dc.contributor.authorNayyar, Rakesh-
dc.contributor.authorTusche, Michael W.-
dc.contributor.authorMetser, Ur-
dc.contributor.authorWright, John J.-
dc.contributor.authorMak, Tak W.-
dc.contributor.authorSiu, Lillian L.-
dc.date.accessioned2020-11-17T14:55:27Z-
dc.date.available2020-11-17T14:55:27Z-
dc.date.issued2010-
dc.identifier.citationMolecular Cancer Therapeutics, 2010, v. 9, n. 3, p. 751-760-
dc.identifier.issn1535-7163-
dc.identifier.urihttp://hdl.handle.net/10722/291953-
dc.description.abstractThe aims of this study were to further define the safety of sorafenib and erlotinib, given at their full approved monotherapy doses, and to correlate pharmacokinetic and pharmacodynamic markers with clinical outcome. In addition, a novel pharmacodynamic marker based on the real-time measurement of RAF signal transduction capacity (STC) is described. Sorafenib was administered alone for a 1-week run-in period, and then both drugs were given together continuously. RAF STC was assessed in peripheral blood monocytes prior to erlotinib initiation. Epidermal growth factor receptor (EGFR) expression and K-RAS mutations were measured in archival tumor samples. Changes in pERK and CD31 were determined in fresh tumor biopsies obtained pretreatment, prior to erlotinib dosing, and during the administration of both drugs. In addition, positron emission tomography-computed tomography scans and pharmacokinetic assessments were done. Eleven patients received a total of 57 cycles (median, 5; range, 1-10). Only four patients received full doses of both drugs for the entire study course, with elevation of liver enzymes being the main reason for dose reductions and delays. Among 10 patients evaluable for response, 8 experienced tumor stabilization of ≥4 cycles. Pharmacokinetic analysis revealed no significant interaction of erlotinib with sorafenib. Sorafenib-induced decrease in RAF-STC showed statistically significant correlation with time-to-progression in seven patients. Other pharmacodynamic markers did not correlate with clinical outcome. This drug combination resulted in promising clinical activity in solid tumor patients although significant toxicity warrants close monitoring. RAF-STC deserves further study as a predictive marker for sorafenib. ©2010 AACR.-
dc.languageeng-
dc.relation.ispartofMolecular Cancer Therapeutics-
dc.titlePhase I combination of sorafenib and erlotinib therapy in solid tumors: Safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort-
dc.typeArticle-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1158/1535-7163.MCT-09-0868-
dc.identifier.pmid20197396-
dc.identifier.pmcidPMC2838726-
dc.identifier.scopuseid_2-s2.0-77949695492-
dc.identifier.volume9-
dc.identifier.issue3-
dc.identifier.spage751-
dc.identifier.epage760-
dc.identifier.isiWOS:000278487300021-
dc.identifier.issnl1535-7163-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats